Navigation Links
InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture
Date:9/17/2009


Optiferrin shown to provide superior performance in cell culture and addresses the need for animal-free transferrin in many applications including Stem Cells, Primary Cells, Hybridoma Cells and Chinese Hamster Ovary (CHO) cells.

Fort Collins, CO September 17, 2009 / b3c newswire / C InVitria today announced the launch of Optiferrin, a high performance, well-defined and animal-free recombinant transferrin for use in mammalian cell culture. Optiferrin is a cell culture supplement which supports cell growth by regulating the amount of iron transported to the cell. Since iron is required for healthy cell culture performance, it is a critical component to reach optimal performance.

Optiferrin has undergone extensive testing by our beta customers since June 2009. They have formulated Optiferrin into their cell culture media to provide maximum performance and they liked their results. We are delighted to be able to bring this sort of value to our customers through innovations like Optiferrin, said Scott Deeter, President & CEO of InVitria.

Transferrin is natures way to deliver iron in a non-toxic manner, said Dr. Steve Pettit, InVitrias Director of Cell Culture Development. Our product development, along with beta customer results, confirmed that Optiferrin delivered optimal performance without any cell damage. This alleviates customers concerns about animal-origin infectious contaminants or the headaches caused by addition of elemental iron and iron chelators in cell culture media, said Dr. Pettit.

Optiferrin is a complimentary product to InVitrias other cell culture supplement products, which include Cellastim, Lacromin, Zap-CHO and Zap-Hybridoma.



About InVitria - www.InVitria.com
InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media components and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

For more information about InVitrias product line, contact us at info@InVitria.com or call 1-800-916-8311.


'/>"/>
b3c newswire

Related biology news :

1. InVitria Sponsors ESACT 2009 in Dublin, Ireland
2. InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO
3. InVitria Announces Launch of Recombinant Albumin for Diagnostics
4. UOG scientists successfully compete for research grants
5. McGill/JGH researchers successfully reverse multiple sclerosis in animals
6. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
7. In troubled economic times, BioSquare 2009 successfully serves as business and innovation starter
8. Salk researchers successfully reprogram keratinocytes attached to a single hair
9. Model successfully predicts large river system fish diversity
10. Scientists successfully treat new mouse model of inflammatory bowel disease
11. Researchers successfully simulate photosynthesis and design a better leaf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial ... ...
Breaking Biology News(10 mins):
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose ... lengthy trial and error process by finding the right antidepressant faster. CNSDose ... the doctor-patient relationship through a personalized approach to treatment. , A ...
(Date:5/18/2017)... Mass. (PRWEB) , ... May 18, 2017 , ... ... the procedure on April 28, 2017 at the Prince Of Wales Private Hospital. ... cervical disc at level C6-C7. The patient failed conservative treatments prior to undergoing ...
(Date:5/18/2017)... ... ... NDA Partners Chairman Carl Peck, MD , announced today that Richard Kenley, ... Pharmaceutical Development Business Unit of Cardinal Health, has joined the firm as an Expert ... Chief Operating Officer at Anaborex, Senior VP and General Manager of the San Diego ...
(Date:5/18/2017)... ... May 17, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, is honored that Jay Crowley ... conference in Brussels, Belgium. , Crowley played a crucial role in the development ...
Breaking Biology Technology: